Unusual source of recurrent Corynebacterium bacteraemia in an immunocompromised patient.

BMJ Case Reports
Abdul Rahim Ali Bakhsh, Keir Edward Lewis

Abstract

We describe a unique case of a patient with acute myeloid leukaemia (AML), with recurring infections during chemotherapy from chronic nasal carriage of non-diphtherial Corynebacterium, who was eventually diagnosed as she presented with neutropaenic sepsis. Identifying (often multiple) sources of infection in immunocompromised patients is crucial but deciding whether multiple organisms, which in health are considered as commensals, are actually pathogenic during vulnerable states-can be clinically difficult. Our case highlights the efforts to correctly identify the actual source of this rare organism and the recognition of its pathogenic potential when other illnesses present. We also review the literature of Corynebacteria in patients with haematological malignancies but believe this is the first case of AML to be infected with Corynebacterium presenting during the COVID-19 pandemic with a probable incidental positive swab for SARS-CoV-2.

References

May 1, 1973·Journal of Medical Microbiology·D A Somerville
Apr 1, 1980·British Journal of Diseases of the Chest·T T Bowstead, S M Santiago
May 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·F WalletR J Courcol
Feb 1, 1997·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L. Martínez-MartínezM. A. Muniáin
Sep 2, 2016·Frontiers in Microbiology·Matthew M RamseyKatherine P Lemon
Oct 22, 2016·Emerging Infectious Diseases·William O HahnRobert M Rakita
Dec 6, 2017·Journal of Investigative Medicine High Impact Case Reports·Paurush AmbeshStephan Kamholz
Jan 13, 2018·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·K NudelL Bry
Mar 13, 2019·Journal of Medical Case Reports·Maxim ClauwaertPieter Depuydt
Jul 28, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Bradley J LangfordNick Daneman
Oct 10, 2020·Journal of Hematology & Oncology·Julio García-SuárezUNKNOWN Asociación Madrileña de Hematología y Hemoterapia (AMHH)

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Geographia Medica. Supplement = Geographia Medica. Sonderband
W SixlF Pichler-Semmelrock
Reviews of Infectious Diseases
B A LipskyJ J Plorde
The Journal of Pathology and Bacteriology
P M Rountree, H R Carne
Microbiología : Publicación De La Sociedad Española De Microbiología
E Herrera-AlcarazM Canteras-Jordana
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
P RiegelH Monteil
© 2021 Meta ULC. All rights reserved